

Global Age Related Macular Degeneration Biologic Drug Market Research Report 2022

<https://marketpublishers.com/r/G5A4A6FB771EEN.html>

Date: July 2022

Pages: 300

Price: US\$ 3,450.00 (Single User License)

ID: G5A4A6FB771EEN

Abstracts

Global Age Related Macular Degeneration Biologic Drug Market Overview:
Global Age Related Macular Degeneration Biologic Drug Market Report 2022 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2022-2028. This research study of Age Related Macular Degeneration Biologic Drug involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.

Scope of the Age Related Macular Degeneration Biologic Drug Market
The Age Related Macular Degeneration Biologic Drug Market Research report incorporate value chain analysis for each of the product type. Value chain analysis offers in depth information about value addition at each stage. The study includes drivers and restraints for Age Related Macular Degeneration Biologic Drug Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting the growth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Age Related Macular Degeneration Biologic Drug Market helps user to make precise decision in order to expand their market presence and increase market share.

Impact of COVID-19 on Age Related Macular Degeneration Biologic Drug Market
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in

December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Age Related Macular Degeneration Biologic Drug market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Global Age Related Macular Degeneration Biologic Drug Market Segmentation
Global Age Related Macular Degeneration Biologic Drug Market Research report comprises of Porter's five forces analysis to do the detail study about its each segmentation like Product segmentation, End user/application segment analysis and Major key players analysis mentioned as below;

By Type, Age Related Macular Degeneration Biologic Drug market has been segmented into:

- Ranibizumab
- Bevacizumab
- Aflibercept

By Application, Age Related Macular Degeneration Biologic Drug market has been segmented into:

- Outpatient Surgery Center
- Eye Clinic
- Hospital

Regional Analysis:

- North America (U.S., Canada, Mexico)
- Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
- South America (Brazil, Argentina, Rest of SA)
- Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)

Competitive Landscape:

Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market. The Age Related Macular Degeneration Biologic Drug market study focused on including all the

primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Age Related Macular Degeneration Biologic Drug market.

Top Key Players Covered in Age Related Macular Degeneration Biologic Drug market are:

Alimera Sciences
Eli Lilly
Novartis
Ophthotech Corporation
Regeneron
Bayer
Genentech
Allergan
Merck
Acucela
Valeant

Objective to buy this Report:

1. Age Related Macular Degeneration Biologic Drug analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Age Related Macular Degeneration Biologic Drug market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.

Contents

CHAPTER 1: INTRODUCTION

- 1.1 RESEARCH OBJECTIVES
- 1.2 RESEARCH METHODOLOGY
- 1.3 RESEARCH PROCESS
- 1.4 SCOPE AND COVERAGE
 - 1.4.1 MARKET DEFINITION
 - 1.4.2 KEY QUESTIONS ANSWERED
- 1.5 MARKET SEGMENTATION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: GROWTH OPPORTUNITIES BY SEGMENT

- 3.1 BY TYPE
- 3.2 BY APPLICATION

CHAPTER 4: MARKET LANDSCAPE

- 4.1 PORTER'S FIVE FORCES ANALYSIS
 - 4.1.1 BARGAINING POWER OF SUPPLIER
 - 4.1.2 THREAT OF NEW ENTRANTS
 - 4.1.3 THREAT OF SUBSTITUTES
 - 4.1.4 COMPETITIVE RIVALRY
 - 4.1.5 BARGAINING POWER AMONG BUYERS
- 4.2 INDUSTRY VALUE CHAIN ANALYSIS
- 4.3 MARKET DYNAMICS
 - 4.3.1 DRIVERS
 - 4.3.2 RESTRAINTS
 - 4.3.3 OPPORTUNITIES
 - 4.5.4 CHALLENGES
- 4.4 PESTLE ANALYSIS
- 4.5 TECHNOLOGICAL ROADMAP
- 4.6 REGULATORY LANDSCAPE
- 4.7 SWOT ANALYSIS
- 4.8 PRICE TREND ANALYSIS
- 4.9 PATENT ANALYSIS

- 4.10 ANALYSIS OF THE IMPACT OF COVID-19
 - 4.10.1 IMPACT ON THE OVERALL MARKET
 - 4.10.2 IMPACT ON THE SUPPLY CHAIN
 - 4.10.3 IMPACT ON THE KEY MANUFACTURERS
 - 4.10.4 IMPACT ON THE PRICING

CHAPTER 5: AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET BY TYPE

- 5.1 AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
- 5.2 AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET OVERVIEW
- 5.3 RANIBIZUMAB
 - 5.3.1 INTRODUCTION AND MARKET OVERVIEW
 - 5.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
 - 5.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
 - 5.3.4 RANIBIZUMAB: GEOGRAPHIC SEGMENTATION
- 5.4 BEVACIZUMAB
 - 5.4.1 INTRODUCTION AND MARKET OVERVIEW
 - 5.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
 - 5.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
 - 5.4.4 BEVACIZUMAB: GEOGRAPHIC SEGMENTATION
- 5.5 AFLIBERCEPT
 - 5.5.1 INTRODUCTION AND MARKET OVERVIEW
 - 5.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
 - 5.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
 - 5.5.4 AFLIBERCEPT: GEOGRAPHIC SEGMENTATION

CHAPTER 6: AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET BY APPLICATION

- 6.1 AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET OVERVIEW SNAPSHOT AND GROWTH ENGINE
- 6.2 AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET OVERVIEW
- 6.3 OUTPATIENT SURGERY CENTER
 - 6.3.1 INTRODUCTION AND MARKET OVERVIEW
 - 6.3.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)

- 6.3.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
- 6.3.4 OUTPATIENT SURGERY CENTER: GEOGRAPHIC SEGMENTATION
- 6.4 EYE CLINIC
 - 6.4.1 INTRODUCTION AND MARKET OVERVIEW
 - 6.4.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
 - 6.4.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
 - 6.4.4 EYE CLINIC: GEOGRAPHIC SEGMENTATION
- 6.5 HOSPITAL
 - 6.5.1 INTRODUCTION AND MARKET OVERVIEW
 - 6.5.2 HISTORIC AND FORECASTED MARKET SIZE (2016-2028F)
 - 6.5.3 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
 - 6.5.4 HOSPITAL: GEOGRAPHIC SEGMENTATION

CHAPTER 7: COMPANY PROFILES AND COMPETITIVE ANALYSIS

- 7.1 COMPETITIVE LANDSCAPE
 - 7.1.1 COMPETITIVE POSITIONING
 - 7.1.2 AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG SALES AND MARKET SHARE BY PLAYERS
 - 7.1.3 INDUSTRY BCG MATRIX
 - 7.1.4 HEAT MAP ANALYSIS
 - 7.1.5 AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG INDUSTRY CONCENTRATION RATIO (CR5 AND HHI)
 - 7.1.6 TOP 5 AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG PLAYERS MARKET SHARE
 - 7.1.7 MERGERS AND ACQUISITIONS
 - 7.1.8 BUSINESS STRATEGIES BY TOP PLAYERS
- 7.2 ALIMERA SCIENCES
 - 7.2.1 COMPANY OVERVIEW
 - 7.2.2 KEY EXECUTIVES
 - 7.2.3 COMPANY SNAPSHOT
 - 7.2.4 OPERATING BUSINESS SEGMENTS
 - 7.2.5 PRODUCT PORTFOLIO
 - 7.2.6 BUSINESS PERFORMANCE
 - 7.2.7 KEY STRATEGIC MOVES AND RECENT DEVELOPMENTS
 - 7.2.8 SWOT ANALYSIS
- 7.3 ELI LILLY
- 7.4 NOVARTIS
- 7.5 OPHTHOTECH CORPORATION

- 7.6 REGENERON
- 7.7 BAYER
- 7.8 GENENTECH
- 7.9 ALLERGAN
- 7.10 MERCK
- 7.11 ACUCELA
- 7.12 VALEANT

CHAPTER 8: GLOBAL AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028

- 8.1 MARKET OVERVIEW
- 8.2 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
 - 8.2.1 RANIBIZUMAB
 - 8.2.2 BEVACIZUMAB
 - 8.2.3 AFLIBERCEPT
- 8.3 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
 - 8.3.1 OUTPATIENT SURGERY CENTER
 - 8.3.2 EYE CLINIC
 - 8.3.3 HOSPITAL

CHAPTER 9: NORTH AMERICA AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028

- 9.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
- 9.2 IMPACT OF COVID-19
- 9.3 KEY PLAYERS
- 9.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
- 9.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
 - 9.4.1 RANIBIZUMAB
 - 9.4.2 BEVACIZUMAB
 - 9.4.3 AFLIBERCEPT
- 9.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
 - 9.5.1 OUTPATIENT SURGERY CENTER
 - 9.5.2 EYE CLINIC
 - 9.5.3 HOSPITAL
- 9.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
 - 9.6.1 U.S.
 - 9.6.2 CANADA

9.6.3 MEXICO

CHAPTER 10: EUROPE AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028

10.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

10.2 IMPACT OF COVID-19

10.3 KEY PLAYERS

10.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

10.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE

10.4.1 RANIBIZUMAB

10.4.2 BEVACIZUMAB

10.4.3 AFLIBERCEPT

10.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION

10.5.1 OUTPATIENT SURGERY CENTER

10.5.2 EYE CLINIC

10.5.3 HOSPITAL

10.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY

10.6.1 GERMANY

10.6.2 U.K.

10.6.3 FRANCE

10.6.4 ITALY

10.6.5 RUSSIA

10.6.6 SPAIN

10.6.7 REST OF EUROPE

CHAPTER 11: ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028

11.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

11.2 IMPACT OF COVID-19

11.3 KEY PLAYERS

11.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

11.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE

11.4.1 RANIBIZUMAB

11.4.2 BEVACIZUMAB

11.4.3 AFLIBERCEPT

11.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION

11.5.1 OUTPATIENT SURGERY CENTER

- 11.5.2 EYE CLINIC
- 11.5.3 HOSPITAL
- 11.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
 - 11.6.1 CHINA
 - 11.6.2 INDIA
 - 11.6.3 JAPAN
 - 11.6.4 SINGAPORE
 - 11.6.5 AUSTRALIA
 - 11.6.6 NEW ZEALAND
 - 11.6.7 REST OF APAC

CHAPTER 12: MIDDLE EAST & AFRICA AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028

- 12.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
- 12.2 IMPACT OF COVID-19
- 12.3 KEY PLAYERS
- 12.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES
- 12.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE
 - 12.4.1 RANIBIZUMAB
 - 12.4.2 BEVACIZUMAB
 - 12.4.3 AFLIBERCEPT
- 12.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION
 - 12.5.1 OUTPATIENT SURGERY CENTER
 - 12.5.2 EYE CLINIC
 - 12.5.3 HOSPITAL
- 12.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY
 - 12.6.1 TURKEY
 - 12.6.2 SAUDI ARABIA
 - 12.6.3 IRAN
 - 12.6.4 UAE
 - 12.6.5 AFRICA
 - 12.6.6 REST OF MEA

CHAPTER 13: SOUTH AMERICA AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028

- 13.1 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

13.2 IMPACT OF COVID-19

13.3 KEY PLAYERS

13.4 KEY MARKET TRENDS, GROWTH FACTORS AND OPPORTUNITIES

13.4 HISTORIC AND FORECASTED MARKET SIZE BY TYPE

13.4.1 RANIBIZUMAB

13.4.2 BEVACIZUMAB

13.4.3 AFLIBERCEPT

13.5 HISTORIC AND FORECASTED MARKET SIZE BY APPLICATION

13.5.1 OUTPATIENT SURGERY CENTER

13.5.2 EYE CLINIC

13.5.3 HOSPITAL

13.6 HISTORIC AND FORECAST MARKET SIZE BY COUNTRY

13.6.1 BRAZIL

13.6.2 ARGENTINA

13.6.3 REST OF SA

CHAPTER 14 INVESTMENT ANALYSIS

CHAPTER 15 ANALYST VIEWPOINT AND CONCLUSION

List Of Tables

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY

TABLE 002. AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET BARGAINING POWER OF SUPPLIERS

TABLE 003. AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET BARGAINING POWER OF CUSTOMERS

TABLE 004. AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET COMPETITIVE RIVALRY

TABLE 005. AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET THREAT OF NEW ENTRANTS

TABLE 006. AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET THREAT OF SUBSTITUTES

TABLE 007. AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET BY TYPE

TABLE 008. RANIBIZUMAB MARKET OVERVIEW (2016-2028)

TABLE 009. BEVACIZUMAB MARKET OVERVIEW (2016-2028)

TABLE 010. AFLIBERCEPT MARKET OVERVIEW (2016-2028)

TABLE 011. AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET BY APPLICATION

TABLE 012. OUTPATIENT SURGERY CENTER MARKET OVERVIEW (2016-2028)

TABLE 013. EYE CLINIC MARKET OVERVIEW (2016-2028)

TABLE 014. HOSPITAL MARKET OVERVIEW (2016-2028)

TABLE 015. NORTH AMERICA AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET, BY TYPE (2016-2028)

TABLE 016. NORTH AMERICA AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET, BY APPLICATION (2016-2028)

TABLE 017. N AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET, BY COUNTRY (2016-2028)

TABLE 018. EUROPE AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET, BY TYPE (2016-2028)

TABLE 019. EUROPE AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET, BY APPLICATION (2016-2028)

TABLE 020. AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET, BY COUNTRY (2016-2028)

TABLE 021. ASIA PACIFIC AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET, BY TYPE (2016-2028)

TABLE 022. ASIA PACIFIC AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET, BY APPLICATION (2016-2028)

TABLE 023. AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET, BY COUNTRY (2016-2028)

TABLE 024. MIDDLE EAST & AFRICA AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET, BY TYPE (2016-2028)

TABLE 025. MIDDLE EAST & AFRICA AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET, BY APPLICATION (2016-2028)

TABLE 026. AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET, BY COUNTRY (2016-2028)

TABLE 027. SOUTH AMERICA AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET, BY TYPE (2016-2028)

TABLE 028. SOUTH AMERICA AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET, BY APPLICATION (2016-2028)

TABLE 029. AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET, BY COUNTRY (2016-2028)

TABLE 030. ALIMERA SCIENCES: SNAPSHOT

TABLE 031. ALIMERA SCIENCES: BUSINESS PERFORMANCE

TABLE 032. ALIMERA SCIENCES: PRODUCT PORTFOLIO

TABLE 033. ALIMERA SCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 033. ELI LILLY: SNAPSHOT

TABLE 034. ELI LILLY: BUSINESS PERFORMANCE

TABLE 035. ELI LILLY: PRODUCT PORTFOLIO

TABLE 036. ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 036. NOVARTIS: SNAPSHOT

TABLE 037. NOVARTIS: BUSINESS PERFORMANCE

TABLE 038. NOVARTIS: PRODUCT PORTFOLIO

TABLE 039. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 039. OPHTHOTECH CORPORATION: SNAPSHOT

TABLE 040. OPHTHOTECH CORPORATION: BUSINESS PERFORMANCE

TABLE 041. OPHTHOTECH CORPORATION: PRODUCT PORTFOLIO

TABLE 042. OPHTHOTECH CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 042. REGENERON: SNAPSHOT

TABLE 043. REGENERON: BUSINESS PERFORMANCE

TABLE 044. REGENERON: PRODUCT PORTFOLIO

TABLE 045. REGENERON: KEY STRATEGIC MOVES AND DEVELOPMENTS

TABLE 045. BAYER: SNAPSHOT

TABLE 046. BAYER: BUSINESS PERFORMANCE

TABLE 047. BAYER: PRODUCT PORTFOLIO
TABLE 048. BAYER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 048. GENENTECH: SNAPSHOT
TABLE 049. GENENTECH: BUSINESS PERFORMANCE
TABLE 050. GENENTECH: PRODUCT PORTFOLIO
TABLE 051. GENENTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 051. ALLERGAN: SNAPSHOT
TABLE 052. ALLERGAN: BUSINESS PERFORMANCE
TABLE 053. ALLERGAN: PRODUCT PORTFOLIO
TABLE 054. ALLERGAN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 054. MERCK: SNAPSHOT
TABLE 055. MERCK: BUSINESS PERFORMANCE
TABLE 056. MERCK: PRODUCT PORTFOLIO
TABLE 057. MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 057. ACUCELA: SNAPSHOT
TABLE 058. ACUCELA: BUSINESS PERFORMANCE
TABLE 059. ACUCELA: PRODUCT PORTFOLIO
TABLE 060. ACUCELA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 060. VALEANT: SNAPSHOT
TABLE 061. VALEANT: BUSINESS PERFORMANCE
TABLE 062. VALEANT: PRODUCT PORTFOLIO
TABLE 063. VALEANT: KEY STRATEGIC MOVES AND DEVELOPMENTS

List Of Figures

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS

FIGURE 002. SCOPE OF THE STUDY

FIGURE 003. AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET OVERVIEW BY REGIONS

FIGURE 004. PORTER'S FIVE FORCES ANALYSIS

FIGURE 005. BARGAINING POWER OF SUPPLIERS

FIGURE 006. COMPETITIVE RIVALRY FIGURE 007. THREAT OF NEW ENTRANTS

FIGURE 008. THREAT OF SUBSTITUTES

FIGURE 009. VALUE CHAIN ANALYSIS

FIGURE 010. PESTLE ANALYSIS

FIGURE 011. AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET OVERVIEW BY TYPE

FIGURE 012. RANIBIZUMAB MARKET OVERVIEW (2016-2028)

FIGURE 013. BEVACIZUMAB MARKET OVERVIEW (2016-2028)

FIGURE 014. AFLIBERCEPT MARKET OVERVIEW (2016-2028)

FIGURE 015. AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET OVERVIEW BY APPLICATION

FIGURE 016. OUTPATIENT SURGERY CENTER MARKET OVERVIEW (2016-2028)

FIGURE 017. EYE CLINIC MARKET OVERVIEW (2016-2028)

FIGURE 018. HOSPITAL MARKET OVERVIEW (2016-2028)

FIGURE 019. NORTH AMERICA AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET OVERVIEW BY COUNTRY (2016-2028)

FIGURE 020. EUROPE AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET OVERVIEW BY COUNTRY (2016-2028)

FIGURE 021. ASIA PACIFIC AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET OVERVIEW BY COUNTRY (2016-2028)

FIGURE 022. MIDDLE EAST & AFRICA AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET OVERVIEW BY COUNTRY (2016-2028)

FIGURE 023. SOUTH AMERICA AGE RELATED MACULAR DEGENERATION BIOLOGIC DRUG MARKET OVERVIEW BY COUNTRY (2016-2028)

I would like to order

Product name: Global Age Related Macular Degeneration Biologic Drug Market Research Report 2022

Product link: <https://marketpublishers.com/r/G5A4A6FB771EEN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5A4A6FB771EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970